KR100978971B1 - 마크롤리드 함유 제약 조성물 - Google Patents

마크롤리드 함유 제약 조성물 Download PDF

Info

Publication number
KR100978971B1
KR100978971B1 KR1020047005958A KR20047005958A KR100978971B1 KR 100978971 B1 KR100978971 B1 KR 100978971B1 KR 1020047005958 A KR1020047005958 A KR 1020047005958A KR 20047005958 A KR20047005958 A KR 20047005958A KR 100978971 B1 KR100978971 B1 KR 100978971B1
Authority
KR
South Korea
Prior art keywords
amino
formula
pharmaceutically acceptable
compound
propane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047005958A
Other languages
English (en)
Korean (ko)
Other versions
KR20040052250A (ko
Inventor
요세프 고트프리트 마인가스너
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0127341A external-priority patent/GB0127341D0/en
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20040052250A publication Critical patent/KR20040052250A/ko
Application granted granted Critical
Publication of KR100978971B1 publication Critical patent/KR100978971B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020047005958A 2001-10-23 2002-10-22 마크롤리드 함유 제약 조성물 Expired - Fee Related KR100978971B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0125443.2A GB0125443D0 (en) 2001-10-23 2001-10-23 Organic Compounds
GB0125443.2 2001-10-23
GB0127341A GB0127341D0 (en) 2001-11-14 2001-11-14 Organic compounds
GB0127341.6 2001-11-14
PCT/EP2002/011799 WO2003035068A1 (en) 2001-10-23 2002-10-22 Macrolides containing pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020097021354A Division KR20090114483A (ko) 2001-10-23 2002-10-22 마크롤리드 함유 제약 조성물

Publications (2)

Publication Number Publication Date
KR20040052250A KR20040052250A (ko) 2004-06-22
KR100978971B1 true KR100978971B1 (ko) 2010-08-30

Family

ID=26246689

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020047005958A Expired - Fee Related KR100978971B1 (ko) 2001-10-23 2002-10-22 마크롤리드 함유 제약 조성물
KR1020097021354A Ceased KR20090114483A (ko) 2001-10-23 2002-10-22 마크롤리드 함유 제약 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097021354A Ceased KR20090114483A (ko) 2001-10-23 2002-10-22 마크롤리드 함유 제약 조성물

Country Status (19)

Country Link
US (1) US7259170B2 (https=)
EP (1) EP1439838A1 (https=)
JP (1) JP2005509634A (https=)
KR (2) KR100978971B1 (https=)
CN (1) CN1307993C (https=)
AU (1) AU2002346859C1 (https=)
BR (1) BR0213463A (https=)
CA (1) CA2458690C (https=)
EC (1) ECSP045086A (https=)
GB (1) GB0125443D0 (https=)
HU (1) HUP0402108A3 (https=)
IL (1) IL160973A0 (https=)
MX (1) MXPA04003738A (https=)
NO (1) NO20042074L (https=)
NZ (1) NZ532412A (https=)
PL (1) PL368533A1 (https=)
RU (1) RU2321402C2 (https=)
WO (1) WO2003035068A1 (https=)
ZA (1) ZA200401711B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512946A (ja) * 2001-05-09 2005-05-12 ノバルティス アクチエンゲゼルシャフト 選択的免疫調節法
BR0306811A (pt) 2002-01-11 2004-10-26 Sankyo Co Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
JP2005272453A (ja) 2004-02-24 2005-10-06 Sankyo Co Ltd アミノアルコール化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0427680A1 (en) * 1989-11-09 1991-05-15 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
EP0627046A1 (en) * 1992-02-19 1994-12-07 Lucas Industries Public Limited Company Fuel pumping apparatus

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68921934T2 (de) 1988-06-29 1995-10-19 Merck & Co Inc Immunsuppressives Agens.
US5352671A (en) * 1989-11-09 1994-10-04 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
GB2252041A (en) * 1991-01-23 1992-07-29 Fujisawa Pharmaceutical Co Use of macrolide compounds in treatment of autoimmune myocarditis
CA2106483A1 (en) * 1991-03-19 1992-09-20 Vithal J. Rajadhyaksha Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5604229A (en) * 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
JPH08507789A (ja) 1993-03-17 1996-08-20 アボツト・ラボラトリーズ 大環状アミド及び尿素免疫調節剤
US5590460A (en) * 1994-07-19 1997-01-07 Tessera, Inc. Method of making multilayer circuit
DE69524962D1 (de) * 1994-08-22 2002-02-14 Welfide Corp Benzolderivate und deren medizinische verwendung
GB9521322D0 (en) 1995-10-17 1995-12-20 Sandoz Ltd Organic compounds
JPH11209277A (ja) 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
ATE298740T1 (de) * 1997-04-04 2005-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
GB0003932D0 (en) 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
EP1355588B1 (en) 2000-12-22 2007-08-15 Avantec Vascular Corporation Device for delivery of therepeutic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0427680A1 (en) * 1989-11-09 1991-05-15 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
EP0627046A1 (en) * 1992-02-19 1994-12-07 Lucas Industries Public Limited Company Fuel pumping apparatus

Also Published As

Publication number Publication date
US20040192716A1 (en) 2004-09-30
CA2458690A1 (en) 2003-05-01
CA2458690C (en) 2011-01-25
ECSP045086A (es) 2004-06-28
PL368533A1 (en) 2005-04-04
KR20090114483A (ko) 2009-11-03
JP2005509634A (ja) 2005-04-14
WO2003035068A1 (en) 2003-05-01
BR0213463A (pt) 2004-11-09
ZA200401711B (en) 2004-10-21
HUP0402108A3 (en) 2008-02-28
IL160973A0 (en) 2004-08-31
AU2002346859C1 (en) 2008-07-10
NO20042074L (no) 2004-05-19
MXPA04003738A (es) 2004-07-23
CN1307993C (zh) 2007-04-04
AU2002346859B2 (en) 2006-03-02
RU2321402C2 (ru) 2008-04-10
CN1575173A (zh) 2005-02-02
US7259170B2 (en) 2007-08-21
KR20040052250A (ko) 2004-06-22
EP1439838A1 (en) 2004-07-28
RU2004116067A (ru) 2005-04-20
NZ532412A (en) 2006-01-27
HUP0402108A2 (hu) 2005-02-28
GB0125443D0 (en) 2001-12-12

Similar Documents

Publication Publication Date Title
KR101476451B1 (ko) 자가면역성 질환의 치료
US12215111B2 (en) Imidazopyridazine IL-17 inhibitor compounds
US6794410B2 (en) Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
US20080015261A1 (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
JP2007262082A (ja) 多発性硬化症の処置のためのリルゾールの使用
KR100978971B1 (ko) 마크롤리드 함유 제약 조성물
AU2002346859A1 (en) Macrolides containing pharmaceutical compositions
JP2008516961A (ja) 神経変性障害を処置することにおける使用のためのカルバメート化合物
EP1192944B1 (en) Use of pregabalin for treating asthma
JP2558147B2 (ja) 免疫性疾患治療剤
WO2003004010A1 (en) Carbonylamino derivatives useful for obtaining immune regulation
WO2025124501A1 (zh) 1-(3-氨基丙基)取代环状胺类化合物的用途
HK1060855B (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20130825

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130825

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000